Boundary Capital has announced its latest investment in AB-Polyblok, a revolutionary technology which has the potential to treat, and potentially partially reverse, the effects of Alzheimer’s Disease.

AB-Polyblock has a novel potential drug therapy for the treatment of Alzheimer’s Disease. The drug was conceived and developed after independent, private research.

Alzheimer’s Disease is the largest cause of dementia and is a growing problem due to ageing society. The total estimated worldwide cost of dementia is US$818 billion in 2015, which represents 1.09% of global GDP. There are an estimated 46.8 million people worldwide living with dementia in 2015. This number will almost double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050.

Boundary Capital’s model is to appoint experienced, investing directors as Venturers typically acting as executive directors or Chairman and assisting with commercialisation as well as helping to de-risk the proposition for investors and entrepreneurs alike. Dr Adrian Parton MBE, who is also a Partner at Boundary Capital, is the Venturer on AB-Polyblok.

Parton says: “I’ve been involved with commercialising life science propositions, and the opportunity to help get a potentially revolutionary therapeutic to help Alzheimer’s Disease was a chance in a lifetime for such a pervasive and impactful condition. It’s clear to me that the company has something very special here and it fits our business model perfectly.”

Dan Somers, the Managing Partner of Boundary Capital says: “We’re delighted to invest in this technology with our experienced Venturer to help to productise and take it to market.”

Write a comment:


Your email address will not be published.

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA